Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
Curated scientific studies about autoimmune diseases.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
Scientists have identified a common gut fungus called Engyodontium that appears to worsen Crohn's disease by crowding out beneficial bacteri...
Read More — Gut Fungus Engyodontium Disrupts Protective Bacteria and Worsens Inflammation in Crohn's Disease »A 2026 PRISMA-based systematic review in the Journal of Dermatological Treatment examined every approved and guideline-recommended treatment...
Read More — Ruxolitinib Cream and Standard Therapies for Vitiligo: A 2026 Systematic Review of Approved and Guideline-Recommended Treatments »Phase 3 results announced in February 2026 show that obinutuzumab, an anti-CD20 monoclonal antibody, achieved significantly higher rates of...
Read More — Phase 3 MAJESTY Trial Shows Obinutuzumab Achieves Superior Complete Remission Over Tacrolimus in Primary Membranous Nephropathy »A pivotal clinical trial published in Nature Medicine in January 2026 found that an implantable vagus nerve stimulation device significantly...
Read More — Implantable Vagus Nerve Stimulator Reduces Rheumatoid Arthritis Activity in Pivotal RESET-RA Trial, Published in Nature Medicine »A 2026 retrospective study found that efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, achieved recovery outcomes in Guillain-Barre sy...
Read More — Efgartigimod Shows Comparable Efficacy to IVIG in Guillain-Barre Syndrome with Faster Neurological Recovery »A phase 3 clinical trial found that ianalumab, a novel B-cell targeting agent, significantly extended the time patients with immune thromboc...
Read More — Ianalumab plus Eltrombopag Extends Time to Treatment Failure in Previously Treated Immune Thrombocytopenia: Phase 3 VAYHIT2 Trial »A comprehensive systematic review published in Best Practice and Research Clinical Rheumatology assessed the landscape of emerging therapies...
Read More — Novel Therapies in Sjögren's Disease: Systematic Review Finds Ianalumab and Telitacicept Lead a New Era of Targeted Treatment »A major phase 3 clinical trial published in the New England Journal of Medicine found that atacicept, a dual BAFF/APRIL inhibitor, reduced p...
Read More — Atacicept Reduces Proteinuria by 46% in Phase 3 IgA Nephropathy Trial, ORIGIN 3 Study Shows »A phase 3 clinical trial published in the New England Journal of Medicine found that icotrokinra, the first oral peptide to selectively bloc...
Read More — First-in-Class Oral IL-23 Receptor Blocker Icotrokinra Achieves 65% Skin Clearance in Phase 3 Psoriasis Trial »A systematic review and meta-analysis of 21 randomized controlled trials involving 1,610 patients with Hashimoto thyroiditis found that sele...
Read More — Selenium Supplementation Reduces Thyroid Antibodies in Hashimoto Thyroiditis: Systematic Review and Meta-Analysis of 21 Randomized Controlled Trials »A Cell Press review in Trends in Molecular Medicine surveys emerging therapies for anti-NMDA receptor encephalitis, including IL-6 inhibitor...
Read More — New Review Maps Future Treatment Directions for Anti-NMDA Receptor Encephalitis »A landmark Dutch randomized trial published in the New England Journal of Medicine has found that methotrexate, long used as a second-line t...
Read More — PREDMETH Trial: Methotrexate Noninferior to Prednisone as First-Line Therapy for Pulmonary Sarcoidosis »